title: Pharmacobiological Approach for the Clinical Development of Ruxolitinib in Myeloproliferative Neoplasms.
abstract: Ruxolitinib, a JAK1 and JAK2 inhibitor drug, has recently been approved for the treatment of patients with high- or intermediate-risk myelofibrosis with symptomatic splenomegaly. Ruxolitinib is the first clinically useful targeted therapy in Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs). The aim of this paper is to indicate pharmacobiological aspects of ruxolitinib within the potential context of MPNs. Pharmacobiological assessments, in addition to knowledge of the risk profile for ruxolitinib in MPNs, are required. We propose hypotheses based on our experience in a splenectomized MPN patient with hyperproliferative bone marrow and moderate fibrosis receiving ruxolitinib. We believe that a true clinical development approach for this drug should include pharmacobiological assessments for ruxolitinib in addition to the disease risk profile of MPNs.
authors: Hacettepe University Faculty of Medicine, Department of Hematology, Ankara, Turkey E-mail: eylemeli@gmail.com.
authors: Eylem
authors: E
authors: Eliaçık
authors: Ayşe
authors: A
authors: Işık
authors: Salih
authors: S
authors: Aksu
authors: Ayşegül
authors: A
authors: Üner
authors: Yahya
authors: Y
authors: Büyükaşık
authors: Nilgün
authors: N
authors: Sayınalp
authors: Hakan
authors: H
authors: Göker
authors: Osman I
authors: OI
authors: Özcebe
authors: İbrahim C
authors: İC
authors: Haznedaroğlu
mesh_terms: D001853:Bone Marrow / Q000473:pathology; D003131:Combined Modality Therapy; D018450:Disease Progression; D005260:Female; D005355:Fibrosis; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D053614:Janus Kinase 2 / Q000037:antagonists & inhibitors* / Q000235:genetics; D007937:Leukapheresis; D008875:Middle Aged; D009196:Myeloproliferative Disorders / Q000188:drug therapy; D009570:Nitriles; D018962:Phlebotomy; D017354:Point Mutation; D011087:Polycythemia Vera / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology / Q000601:surgery; D047428:Protein Kinase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D011720:Pyrazoles / Q000494:pharmacology / Q000627:therapeutic use*; D011743:Pyrimidines; D011799:Quinazolines / Q000627:therapeutic use; D013156:Splenectomy; D013163:Splenomegaly / Q000209:etiology / Q000601:surgery
chemical_list: D009570:Nitriles; D047428:Protein Kinase Inhibitors; D011720:Pyrazoles; D011743:Pyrimidines; D011799:Quinazolines; C540383:ruxolitinib; C507924:JAK2 protein, human; D053614:Janus Kinase 2; C021139:anagrelide; D006918:Hydroxyurea